Equillium (EQ) Assets Average (2018 - 2026)
Equillium (EQ) posted quarterly Assets Average of $47.5 million for Q1 2026, up 124.34% year-over-year from $21.2 million in Q1 2025, and up 43.04% quarter-over-quarter from $33.2 million in Q4 2025.
Equillium (EQ) Assets Average (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Assets Average for 9 consecutive years, with $47.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 124.34% year-over-year to $47.5 million; the TTM figure through Mar 2026 stood at $47.5 million (up 124.34% YoY), while the FY2025 annual figure was $28.7 million, down 24.49% from the prior year.
- Assets Average improved to $47.5 million in Q1 2026 per EQ's latest filing, from $33.2 million in the prior quarter.
- Across five years, Assets Average topped out at $65.3 million in Q2 2023 and bottomed at $14.6 million in Q2 2025.
- Historically, Assets Average has averaged $39.4 million across 5 years, with a median of $38.7 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average tumbled 77.7% — and 2023, when it jumped 183.21%.
- Equillium's Assets Average stood at $35.8 million in 2022, then soared by 47.54% to $52.9 million in 2023, then slumped by 43.21% to $30.0 million in 2024, then rose by 10.54% to $33.2 million in 2025, then jumped by 43.04% to $47.5 million in 2026.
- Business Quant data shows EQ's Assets Average at $47.5 million in Q1 2026, $33.2 million in Q4 2025, and $23.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 60.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.87 Mn |
| Mar 31, 2026 | 47.49 Mn |
| Dec 31, 2025 | 33.20 Mn |
| Sep 30, 2025 | 23.45 Mn |
| Jun 30, 2025 | 14.56 Mn |
| Mar 31, 2025 | 21.17 Mn |
| Dec 31, 2024 | 30.03 Mn |
| Sep 30, 2024 | 38.66 Mn |
| Jun 30, 2024 | 43.23 Mn |
| Mar 31, 2024 | 47.06 Mn |
| Dec 31, 2023 | 52.88 Mn |
| Sep 30, 2023 | 56.99 Mn |
| Jun 30, 2023 | 65.28 Mn |
| Mar 31, 2023 | 47.42 Mn |
| Dec 31, 2022 | 35.84 Mn |
| Sep 30, 2022 | 35.84 Mn |
| Jun 30, 2022 | 23.05 Mn |
| Mar 31, 2022 | 54.23 Mn |
| Dec 31, 2021 | 88.94 Mn |
| Sep 30, 2021 | 96.15 Mn |